企业摘要
季度业绩走势
营业收入
营业利润率
市场偏好度
※ 点击图表可查看该月份的AI分析信息。
营业收入
合并
单独
营业利润
合并
单独
净利润
合并
单独
财务信息
保存为Excel
该期间没有财务信息数据。
~
季度
决算
*单位基准小数点第四位以下的数值标记为'0/-0'
财务指标预测
※ 本预测值是基于历史数据的AI简单估算值，可能与实际业绩存在差异。
企业概况
截至2026年6月
ENCell Co., Ltd. has two business models based on its optimized GMP (manufacturing and quality control) technology for developing multiple cell and gene therapies: advanced biopharmaceutical contract development and manufacturing (CDMO), and development of next-generation cell and gene therapy new drugs. In the advanced biopharmaceutical CDMO business, the company implements clients' various advanced biopharmaceutical source technologies (IP) into drug-grade finished products using its GMP system, which requires GMP production technology, a CDMO business management system, multi-item process technology, a multi-item production workforce, production know-how, and GMP facilities. Because there is currently no standardized production process for advanced biopharmaceuticals, customized production process development and optimization are required for each item.
代表理事
Jang Jonguk
成立日期
2018年3月21日
法人类型
韩国创业板
行业分类
Manufacture of medicinal chemicals
法人注册号
11011-6693918
营业执照号
360-86-01147
电话号码
02-6205-8050
传真号码
公司地址
201 Songpa-daero, Songpa-gu, Seoul
产品与服务
评论